BRENDA CAIN: Open Payments
NPI 1104498039 · SIOUX CITY, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,492 in 85 payments from 16 companies in 2025. Trend: 2023 $1,886 · 2024 $1,555 · 2025 $1,492
Food & beverage: $1,492
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 17 | $302 |
| Vanda Pharmaceuticals Inc. | 9 | $198 |
| Alkermes, Inc. | 11 | $185 |
| E.R. Squibb & Sons, L.L.C. | 12 | $162 |
| Lundbeck LLC | 7 | $148 |
| Neurocrine BioSciences, Inc. | 6 | $95 |
| Teva Pharmaceuticals USA, Inc. | 5 | $92 |
| Axsome Therapeutics, Inc. | 4 | $73 |
| Janssen Pharmaceuticals, Inc | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
Products named: REXULTI, ARISTADA, COBENFY, HETLIOZ, INGREZZA, AUSTEDO XR, FANAPT, Auvelity.
Industry payments across IA — which companies pay providers there.
